BIOMAT Database Logo BIOMAT Database Logo

Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. 1998

J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
Acute Viral Respiratory Diseases Unit, Baylor College of Medicine, Houston, Texas 77030, USA.

The importance and significance of amantadine- or rimantadine-resistant influenza viruses in immunocompromised patients was studied in a population of adult bone marrow transplant (BMT) recipients and patients with leukemia prospectively cultured for respiratory viruses. Influenza A viruses were isolated from 29 patients with acute respiratory illness (14 BMT recipients and 15 patients with leukemia). Fifteen patients (52%) received amantadine (n = 4) or rimantadine (n = 11) therapy. All influenza isolates recovered from six patients shedding virus for > or = 3 days were screened for antiviral susceptibility; resistant isolates were further genetically characterized. Initial influenza isolates were susceptible to amantadine or rimantadine, but subsequent isolates from five of six patients were resistant. Influenza-associated mortality was similar among patients with and without documented antiviral resistance (2 of 5 vs. 5 of 24). We conclude that development of antiviral resistance in immunocompromised individuals should be considered when they have been treated with antivirals and have shed influenza virus for a prolonged period. Isolation procedures should be instituted for all immunocompromised patients with influenza, both during and after therapy with amantadine or rimantadine.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000547 Amantadine An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. 1-Aminoadamantane,Adamantylamine,Adekin,Aman,Amanta,Amanta-HCI-AZU,Amanta-Sulfate-AZU,Amantadin AL,Amantadin AZU,Amantadin Stada,Amantadin-neuraxpharm,Amantadin-ratiopharm,Amantadina Juventus,Amantadina Llorente,Amantadine Hydrochloride,Amantadine Sulfate,Amixx,Cerebramed,Endantadine,Gen-Amantadine,Infecto-Flu,Infex,Mantadix,Midantan,PMS-Amantadine,Symadine,Symmetrel,Viregyt,Wiregyt,tregor,1 Aminoadamantane,AL, Amantadin,AZU, Amantadin,Amanta HCI AZU,Amanta Sulfate AZU,AmantaHCIAZU,AmantaSulfateAZU,Amantadin neuraxpharm,Amantadin ratiopharm,Amantadinneuraxpharm,Amantadinratiopharm,Gen Amantadine,GenAmantadine,Hydrochloride, Amantadine,Infecto Flu,InfectoFlu,Juventus, Amantadina,Llorente, Amantadina,PMS Amantadine,PMSAmantadine,Stada, Amantadin,Sulfate, Amantadine
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine.
January 1992, Current topics in microbiology and immunology,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
[Emergence of amantadine-resistant influenza A viruses].
December 2001, Uirusu,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
Emergence of amantadine-resistant influenza A viruses: epidemiological study.
September 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
Amantadine and rimantadine for influenza A in adults.
April 2006, The Cochrane database of systematic reviews,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
[Amantadine, rimantadine and influenza].
January 1993, Duodecim; laaketieteellinen aikakauskirja,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
Influenza, influenza vaccine, and amantadine/rimantadine.
August 1997, The Journal of family practice,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
[Amantadine and rimantadine against influenza A].
June 1992, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
Amantadine and rimantadine for preventing and treating influenza A in adults.
January 2004, The Cochrane database of systematic reviews,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
Amantadine and rimantadine for preventing and treating influenza A in adults.
January 2000, The Cochrane database of systematic reviews,
J A Englund, and R E Champlin, and P R Wyde, and H Kantarjian, and R L Atmar, and J Tarrand, and H Yousuf, and H Regnery, and A I Klimov, and N J Cox, and E Whimbey
Amantadine and rimantadine for preventing and treating influenza A in adults.
January 2002, The Cochrane database of systematic reviews,
Copied contents to your clipboard!